Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol

Keisuke Koroki, Masaru Wakatsuki, Sadahisa Ogasawara, Hirokazu Makishima, Taro Watabe, Haruka Anzai, Makoto Fujiya, Midori Sawada, Takahiro Tsuchiya, Keiichi Katayama, Ryohei Yoshino, Ryo Izai, Teppei Akatsuka, Chihiro Miwa, Takuya Yonemoto, Sae Yumita, Masanori Inoue, Masato Nakamura, Naoya Kanogawa, Shingo Nakamoto, Kohei Takahashi, Yoshihito Ozawa, Yosuke Inaba, Tomoya Kurokawa, Tetsuro Isozaki, Asahi Takahashi, Jun Kato, Masayuki Ohtsuka, Tatsuya Ohno, Yoshiyuki Ueno, Junji Furuse, Masatoshi Kudo, Hideki Hanaoka, Hitoshi Ishikawa

Open source

DOI: 10.1136/bmjopen-2025-115731
Published: 2026-06
Container: BMJ Open
Publisher: BMJ
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2025-115731,
  title = {Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol},
  author = {Keisuke Koroki and Masaru Wakatsuki and Sadahisa Ogasawara and Hirokazu Makishima and Taro Watabe and Haruka Anzai and Makoto Fujiya and Midori Sawada and Takahiro Tsuchiya and Keiichi Katayama and Ryohei Yoshino and Ryo Izai and Teppei Akatsuka and Chihiro Miwa and Takuya Yonemoto and Sae Yumita and Masanori Inoue and Masato Nakamura and Naoya Kanogawa and Shingo Nakamoto and Kohei Takahashi and Yoshihito Ozawa and Yosuke Inaba and Tomoya Kurokawa and Tetsuro Isozaki and Asahi Takahashi and Jun Kato and Masayuki Ohtsuka and Tatsuya Ohno and Yoshiyuki Ueno and Junji Furuse and Masatoshi Kudo and Hideki Hanaoka and Hitoshi Ishikawa},
  year = {2026},
  journal = {BMJ Open},
  doi = {10.1136/bmjopen-2025-115731},
  url = {https://doi.org/10.1136/bmjopen-2025-115731}
}

RIS

TY  - JOUR
TI  - Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol
AU  - Keisuke Koroki
AU  - Masaru Wakatsuki
AU  - Sadahisa Ogasawara
AU  - Hirokazu Makishima
AU  - Taro Watabe
AU  - Haruka Anzai
AU  - Makoto Fujiya
AU  - Midori Sawada
AU  - Takahiro Tsuchiya
AU  - Keiichi Katayama
AU  - Ryohei Yoshino
AU  - Ryo Izai
AU  - Teppei Akatsuka
AU  - Chihiro Miwa
AU  - Takuya Yonemoto
AU  - Sae Yumita
AU  - Masanori Inoue
AU  - Masato Nakamura
AU  - Naoya Kanogawa
AU  - Shingo Nakamoto
AU  - Kohei Takahashi
AU  - Yoshihito Ozawa
AU  - Yosuke Inaba
AU  - Tomoya Kurokawa
AU  - Tetsuro Isozaki
AU  - Asahi Takahashi
AU  - Jun Kato
AU  - Masayuki Ohtsuka
AU  - Tatsuya Ohno
AU  - Yoshiyuki Ueno
AU  - Junji Furuse
AU  - Masatoshi Kudo
AU  - Hideki Hanaoka
AU  - Hitoshi Ishikawa
PY  - 2026
JO  - BMJ Open
DO  - 10.1136/bmjopen-2025-115731
UR  - https://doi.org/10.1136/bmjopen-2025-115731
ER  -

APA

Koroki, K., Wakatsuki, M., Ogasawara, S., Makishima, H., Watabe, T., Anzai, H., Fujiya, M., Sawada, M., Tsuchiya, T., Katayama, K., Yoshino, R., Izai, R., Akatsuka, T., Miwa, C., Yonemoto, T., Yumita, S., Inoue, M., Nakamura, M., Kanogawa, N., Nakamoto, S., Takahashi, K., Ozawa, Y., Inaba, Y., Kurokawa, T., Isozaki, T., Takahashi, A., Kato, J., Ohtsuka, M., Ohno, T., Ueno, Y., Furuse, J., Kudo, M., Hanaoka, H., & Ishikawa, H. (2026). Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol. BMJ Open. https://doi.org/10.1136/bmjopen-2025-115731

Source records

crossref · retrieved 2026-09-26T03:30:26.277Z